New hope for advanced bladder cancer: SYS6002 takes on chemo in major trial
NCT ID NCT07526792
First seen Apr 18, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This phase 3 trial tests a new drug called SYS6002 against standard chemotherapy for people with advanced bladder cancer that has not responded to platinum chemo and immunotherapy. About 406 adults aged 18-75 will be randomly assigned to receive either SYS6002 or a chemo chosen by their doctor. The main goal is to see if SYS6002 helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.